Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -103.63% is 45% above its 5-year average of -188.72%, near the high end of its 5-year range (-458.23%–-22.59%).
45.64% below its 12-month average of -71.15%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -48.27%.
EBITDA MARGIN
-103.63%
EBITDA MARGIN AVG TTM
-71.15%
EBITDA MARGIN AVG 3Y
-128.08%
EBITDA MARGIN AVG 5Y
-188.72%
EBITDA MARGIN AVG 10Y
-177.30%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-45.64%
CURRENT VS 3Y AVG
+19.09%
CURRENT VS 5Y AVG
+45.09%
CURRENT VS 10Y AVG
+41.55%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Fortress Biotech, Inc.
Market Cap
$68.60M
EBITDA Margin
-103.63%
TTM Avg
-71.15%
3Y Avg
-128.08%
5Y Avg
-188.72%
Market Cap
$68.72M
EBITDA Margin
-8394.83%
TTM Avg
-8394.83%
3Y Avg
-4949.66%
5Y Avg
-3042.42%
Market Cap
$69.19M
EBITDA Margin
-0.04%
TTM Avg
-76.47%
3Y Avg
-54.24%
5Y Avg
-650.20%
Market Cap
$67.66M
EBITDA Margin
0.40%
TTM Avg
5.90%
3Y Avg
-0.59%
5Y Avg
0.99%
Market Cap
$66.56M
EBITDA Margin
-34495.00%
TTM Avg
-19432.00%
3Y Avg
-15233.78%
5Y Avg
-9657.34%
Market Cap
$66.16M
EBITDA Margin
-794.91%
TTM Avg
-458.44%
3Y Avg
-317.77%
5Y Avg
-317.77%
Market Cap
$71.42M
EBITDA Margin
-85.70%
TTM Avg
-57.28%
3Y Avg
-59.72%
5Y Avg
-51.35%
Market Cap
$72.01M
EBITDA Margin
-40176.79%
TTM Avg
-26409.54%
3Y Avg
-18300.96%
5Y Avg
-13878.09%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | $68.60M | -103.63% | -71.15% | -128.08% | -188.72% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.72M | -8394.83% | -8394.83% | -4949.66% | -3042.42% |
| Spero Therapeutics, Inc. (SPRO)vs › | $69.19M | -0.04% | -76.47% | -54.24% | -650.20% |
| Champions Oncology, Inc. (CSBR)vs › | $67.66M | 0.40% | 5.90% | -0.59% | 0.99% |
| Cingulate Inc. (CING)vs › | $66.69M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $66.56M | -34495.00% | -19432.00% | -15233.78% | -9657.34% |
| XBiotech Inc. (XBIT)vs › | $66.16M | -794.91% | -458.44% | -317.77% | -317.77% |
| MindWalk Holdings Corp. (HYFT)vs › | $71.42M | -85.70% | -57.28% | -59.72% | -51.35% |
| Gain Therapeutics, Inc. (GANX)vs › | $72.01M | -40176.79% | -26409.54% | -18300.96% | -13878.09% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.49M | -31.36% | -442.92% | -595.18% | -526.87% |
Gross Margin
62.5%
EBITDA Margin
-103.6%
Operating Margin
-111.0%
Net Margin
163.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -48.27% |
| 2026-03-31 | -37.66% |
| 2025-12-31 | -22.59% |
| 2025-09-30 | -32.07% |
| 2025-06-30 | -215.18% |
| 2025-03-31 | -160.79% |
| 2024-12-31 | -170.24% |
| 2024-09-30 | -128.32% |
| 2024-06-30 | -178.55% |
| 2024-03-31 | -271.49% |
| 2023-12-31 | -89.77% |
| 2023-09-30 | -31.67% |
| 2023-06-30 | -278.41% |
| 2023-03-31 | -458.23% |
| 2022-12-31 | -317.25% |
| 2022-09-30 | -287.40% |
| 2022-06-30 | -257.88% |
| 2022-03-31 | -188.40% |
| 2021-12-31 | -330.05% |
| 2021-09-30 | -228.54% |
| 2021-06-30 | -230.26% |
| 2021-03-31 | -245.23% |
| 2020-12-31 | -166.80% |
| 2020-09-30 | -229.08% |
| 2020-06-30 | -254.46% |
| 2020-03-31 | -156.70% |
| 2019-12-31 | -261.55% |
| 2019-09-30 | -218.08% |
| 2019-06-30 | -261.96% |
| 2019-03-31 | -486.52% |
| 2018-09-30 | -42.04% |
| 2018-06-30 | -37.76% |
| 2018-03-31 | -59.51% |
| 2017-12-31 | -59.45% |
| 2017-09-30 | -67.78% |
| 2017-06-30 | -44.14% |
| 2017-03-31 | -37.51% |
| 2016-12-31 | -145.86% |
| 2016-09-30 | -1646.26% |
| 2016-06-30 | -674.66% |
| 2016-03-31 | -2285.91% |
| 2015-12-31 | -3732.84% |
| 2015-09-30 | -72264.00% |
| 2015-03-31 | -2413.00% |
